Oppenheimer Asset Management Inc. Has $7.24 Million Holdings in Sanofi (NASDAQ:SNY)

Oppenheimer Asset Management Inc. decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 7.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 125,595 shares of the company’s stock after selling 10,156 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Sanofi were worth $7,238,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Stablepoint Partners LLC boosted its stake in shares of Sanofi by 0.8% during the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after buying an additional 189 shares during the last quarter. PDS Planning Inc grew its stake in Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after purchasing an additional 200 shares in the last quarter. Eagle Ridge Investment Management increased its position in shares of Sanofi by 3.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after purchasing an additional 203 shares during the last quarter. Financial Advocates Investment Management raised its stake in shares of Sanofi by 3.4% during the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after purchasing an additional 206 shares in the last quarter. Finally, TCTC Holdings LLC boosted its holdings in shares of Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after buying an additional 210 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Trading Down 3.4 %

SNY stock opened at $47.82 on Friday. Sanofi has a one year low of $45.13 and a one year high of $58.97. The stock has a market cap of $121.36 billion, a price-to-earnings ratio of 24.40, a price-to-earnings-growth ratio of 1.26 and a beta of 0.61. The company has a fifty day moving average price of $55.05 and a two-hundred day moving average price of $52.23. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.55 EPS. Equities analysts anticipate that Sanofi will post 4.27 EPS for the current year.

Wall Street Analyst Weigh In

SNY has been the topic of several analyst reports. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.